Asherman's Syndrome Epidemiology Forecast 2026-2035

Despite advancements in reproductive healthcare, intrauterine adhesions remain an important yet often underrecognized complication of uterine procedures. Yale Medicine evidence indicates that up to 21.5% of women undergoing dilation and curettage may develop adhesions, contributing to the burden of Asherman’s syndrome. The Asherman’s syndrome epidemiology forecast highlights increasing clinical focus on early detection, improved surgical practices, and greater awareness to mitigate reproductive complications associated with this condition.

Asherman’s Syndrome Epidemiology Forecast Report Coverage

The analyst's “Asherman’s Syndrome Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Asherman’s syndrome. It projects the future incidence and prevalence rates of Asherman’s syndrome cases across various populations. The study covers age, gender, and type as major determinants of the Asherman’s syndrome population. The report highlights patterns in the prevalence of Asherman’s syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on Asherman’s syndrome epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Asherman’s Syndrome Understanding: Disease Overview

Asherman’s syndrome refers to the formation of intrauterine adhesions or scar tissue within the uterine cavity, typically following trauma to the endometrium, such as dilation and curettage, postpartum hemorrhage, or surgical procedures. Adhesions can partially or completely obliterate the uterine cavity, leading to menstrual abnormalities, infertility, recurrent miscarriage, or obstetric complications. The syndrome may be underdiagnosed due to asymptomatic cases or limited use of diagnostic imaging. Diagnosis is confirmed via hysteroscopy or imaging modalities. Early recognition permits restoration of uterine anatomy and function.

Asherman’s Syndrome Epidemiology Perspective

The Asherman’s syndrome epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the Asherman’s syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Asherman’s syndrome and their trends. The Asherman’s syndrome detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Orphanet, Asherman’s syndrome is considered a rare gynecological disorder, with global prevalence estimated at approximately 1-5 cases per 10,000 women, although true population prevalence may be underestimated due to undiagnosed asymptomatic cases.
• Yale Medicine indicate intrauterine adhesions associated with Asherman’s syndrome occur in around 1.5% of women undergoing hysterosalpingography (HSG) during infertility evaluations, highlighting its relevance among women assessed for reproductive complications.
• As per Yu Li. et al., 2025, Clinical studies report that 16-45.5% of women may develop intrauterine adhesions following uterine interventions such as miscarriage management, pregnancy termination, or dilation and curettage procedures.
• According to Yale Medicine, women experiencing recurrent miscarriage, the prevalence of intrauterine adhesions linked to Asherman’s syndrome has been reported between 5% and 39%, indicating significantly higher occurrence in high-risk reproductive populations.

Country-wise Asherman’s Syndrome Epidemiology Segment

The Asherman’s syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country-level epidemiology for Asherman’s syndrome remains limited in the scientific literature, with the United States providing the most accessible and specific clinical data among major healthcare markets. Clinical observations in U.S. reproductive medicine show that up to 21.5% of women with a history of dilation and curettage (D&C) may develop intrauterine adhesions, a major etiological pathway associated with the development of the condition. Comparable country-specific datasets for other regions are rarely reported, as diagnosis typically occurs during infertility evaluations or hysteroscopic procedures. Continued clinical research is expected to improve the availability of regional epidemiological insights.

Asherman’s Syndrome: Treatment Overview

Treatment of Asherman’s syndrome is primarily surgical with hysteroscopic adhesiolysis to remove intrauterine scar tissue and restore cavity architecture. Adjuncts such as intrauterine balloon stents or estrogen therapy are often used postoperatively to prevent re‑adhesion. Antibiotic prophylaxis and postoperative monitoring are recommended. Fertility outcomes improve with early intervention, although severe disease may require multiple procedures. In vitro fertilization may be considered if fertility goals are unmet. Long‑term follow‑up ensures restoration of normal menstrual function and reduces the risk of recurrence.

Key Questions Answered

• What are the key findings of Asherman’s syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with Asherman’s syndrome across the 8 major markets during the forecast period?
• What was the country-wise Asherman’s syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of Asherman’s syndrome during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of Asherman’s syndrome during the forecast period of 2026-2035?
• What are the currently available treatments for Asherman’s syndrome?
• What are the disease risks, signs, symptoms, and unmet needs of Asherman’s syndrome?

Scope of the Asherman’s Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Asherman’s syndrome based on several factors.
• Asherman’s Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Asherman’s syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.